Results 31 to 40 of about 180,701 (284)

Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies

Frontiers in Immunology, 2021
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-like symptoms, moderate, severe, critical, and chronic disease.
Darrell O. Ricke
doaj   +1 more source

Compromised SARS-CoV-2-specific placental antibody transfer [PDF]

Cell, 2021
SARS-CoV-2 infection causes more severe disease in pregnant women compared to age-matched non-pregnant women. Whether maternal infection causes changes in the transfer of immunity to infants remains unclear. Maternal infections have previously been associated with compromised placental antibody transfer, but the mechanism underlying this compromised ...
Atyeo, Caroline, Pullen, Krista M., Bordt, Evan A., Fischinger, Stephanie, Burke, John, Michell, Ashlin, Slein, Matthew D., Loos, Carolin, Shook, Lydia L., Boatin, Adeline A., Yockey, Laura J., Pepin, David, Meinsohn, Marie-Charlotte, Nguyen, Ngoc Minh Phuong, Chauvin, Maeva, Roberts, Drucilla, Goldfarb, Ilona T., Matute, Juan D., James, Kaitlyn E., Yonker, Lael M., Bebell, Lisa M., Kaimal, Anjali J., Gray, Kathryn J., Lauffenburger, Douglas A, Edlow, Andrea G., Alter, Galit   +25 more
openaire   +5 more sources

Prevalence and persistence of SARS-CoV2 antibodies among healthcare workers in Oman

Journal of Infection and Public Health, 2021
Objectives: The primary objective is to determine the prevalence of SARS-CoV-2 antibodies persistence among HCWs and specifically among asymptomatic HCWs.
Khalid Al-Naamani, Issa Al-Jahdhami, Wafa Al-Tamtami, Kawther Al-Amri, Murtadha Al-Khabori, Siham Al Sinani, Elias A. Said, Heba Omer, Hamad Al-Bahluli, Saada Al-Ryiami, Saleh Al-Hakmani, Najat Al-Naamani, Ruqaiya Al-Jahwari, Musheera Al-Hinai, Juhaina AlWahaibi   +14 more
doaj   +1 more source

Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43 [PDF]

, 2005
Cross-reactivity between antibodies to different human coronaviruses (HCoVs) has not been systematically studied. By use of Western blot analysis, indirect immunofluorescence assay (IFA), and enzyme-linked immunosorbent assay (ELISA), antigenic cross ...
Che, XY, Cheng, VCC, Hao, W, Liao, ZY, Mei, YB, Pan, YX, Qiu, LW, Wang, YD, Wen, K, Yuen, KY   +9 more
core   +1 more source

Neutralizing antibody titres in SARS-CoV-2 infections [PDF]

Nature Communications, 2021
AbstractThe SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 ...
Lau, Eric H. Y., Tsang, Owen T. Y., Hui, David S. C., Kwan, Mike Y. W., Chan, Wai-hung, Chiu, Susan S., Ko, Ronald L. W., Chan, Kin H., Cheng, Samuel M. S., Perera, Ranawaka A. P. M., Cowling, Benjamin J., Poon, Leo L. M., Peiris, Malik   +12 more
openaire   +3 more sources

Guest edited collection serological study of SARS-CoV-2 antibodies in japanese cats using protein-A/G-based ELISA

BMC Veterinary Research, 2022
Background Little is known about the epidemic status of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cats in Japan due to insufficiently reliable seroepidemiological analysis methods that are easy to use in cats. Results We developed a
Ichiro Imanishi, Ryota Asahina, Shunji Hayashi, Jumpei Uchiyama, Masaharu Hisasue, Masahiro Yamasaki, Yoshiteru Murata, Shigeru Morikawa, Tetsuya Mizutani, Masahiro Sakaguchi   +9 more
doaj   +1 more source

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

Neutralizing antibodies against SARS-CoV-2

Uirusu, 2023
Severe acute respiratory syndrome (SARS) corona virus 2 (SARS-CoV-2) is a novel coronavirus that infects humans and causes respiratory symptoms, resulting in a global pandemic since its appearance in 2019. Neutralizing antibody production is an important immune response following SARS-CoV-2 infection, and a great deal of research has been performed ...
openaire   +2 more sources

Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study

Microorganisms, 2021
While severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes serious morbidity and mortality in humans (coronavirus disease 2019, COVID-19), there is an enormous range of disease outcomes following virus exposures.
Robert E. Sealy, Julia L. Hurwitz
doaj   +1 more source

Post-vaccination antibodies against SARS-CoV-2: Correspondence

Archivos de Prevención de Riesgos Laborales, 2022
Dear Editor, we would like to share ideas on the publication “Post-vaccination antibodies against SARS-CoV-2 in a cohort of workers of a general hospital”(1). In the cohort and with fresh SARS-CoV-2 infections, Sabater Vidal et al. noticed a general decrease in IgG-S and IgG-NP antibodies following the second dosage of the Pfizer-BioNTech vaccine (1 ...
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit   +1 more
openaire   +4 more sources